Sponsors (10)
The bill preserves the current status quo for Medicaid rules and exempts orphan drugs from price negotiation—protecting existing access and avoiding new state administrative costs—while forgoing potential expanded Medicaid benefits, appropriations-funded programs, and federal drug-cost savings, which could raise costs for Medicare, taxpayers, and some patients.
State governments and health-care providers avoid new administrative requirements and implementation costs tied to section 71120, preserving current budgets and operations.
Medicaid programs and beneficiaries continue under existing Title XIX rules instead of new requirements from section 71120, maintaining current eligibility, benefits administration, and protections.
Patients relying on orphan drugs (people with rare diseases and affected Medicare beneficiaries) retain existing access and pricing arrangements because orphan therapies remain excluded from negotiated price limits.
Medicare beneficiaries and U.S. taxpayers may face higher prescription drug spending because orphan drugs remain exempt from price negotiation, reducing potential federal savings.
Low‑income and other Medicaid beneficiaries could lose expanded benefits or protections that section 71120 would have provided, reducing coverage or supports for vulnerable populations.
States, nonprofits, and other entities that planned projects based on appropriations in section 71120(c) will lose that funding and may face program disruptions, contract problems, or budget shortfalls.
Based on analysis of 3 sections of legislative text.
Repeals two enacted provisions to restore prior Medicaid rules and the original orphan‑drug treatment in the drug price negotiation program, and rescinds related appropriations.
Repeals two provisions of a recent law that changed Medicaid and the federal drug price negotiation program, restoring prior law as if those changes never happened and rescinding previously appropriated amounts tied to one of the provisions. One repeal targets an amendment to Title XIX (Medicaid) and the other removes a change to the orphan‑drug exclusion in the Drug Price Negotiation Program, undoing those policy and funding changes.
Introduced September 2, 2025 by Chris Pappas · Last progress September 2, 2025